Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02720627 · ClinicalTrials.gov registry record · Phase 2
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
A Phase 2 study of Acne Vulgaris, sponsored by Cassiopea SpA.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 10
- Study locations
NCT02720627 is a Phase 2 study of Acne Vulgaris that has completed, run by Cassiopea SpA. The registered enrollment target is 27 participants, below the 275-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (90% lower). The trial reports 10 study locations across 4 states.
The verdict
NCT02720627, a Phase 2 study of Acne Vulgaris, has completed, sponsored by Cassiopea SpA.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study is designed to determine the hypothalamic-pituitary-adrenal (HPA) axis suppression potential and pharmacokinetic (PK) properties of CB-03-01 Cream, 1%, applied every twelve hours for two weeks, in pediatric patients 9 to less than 12 years of age with acne vulgaris. Adrenal suppression effects and systemic safety are an important safety concern. The current study is designed to investigate these potential concerns under maximal use conditions.
Conditions Studied
Interventions
- DRUG cortexolone 17α-propionate
Study Locations (10)
Other
- Site 4814 - Częstochowa
- Site 4811 - Katowice
- Site 4813 - Krakow
- Site 4815 - Krakow
- Site 4816 - Rzeszów
- Site 4812 - Szczecin
- Site 4817 - Tarnów
Arkansas
- Site 103 - Fort Smith
California
- Site 101 - San Diego
Texas
- Site 102 - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2016-10-28 |
| Est. Completion | 2018-03-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02720627
The ClinicalTrials.gov registry entry for NCT02720627 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 275-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (90% lower). The listed sponsor is Cassiopea SpA, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which cortexolone 17α-propionate is the first listed.
NCT02720627 reports 10 study locations spanning 4 distinct geographic areas - top geographies include Other, Arkansas, California.
Frequently Asked Questions
What is clinical trial NCT02720627 about?
NCT02720627 is a clinical study titled "An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris". This study is designed to determine the hypothalamic-pituitary-adrenal (HPA) axis suppression potential and pharmacokinetic (PK) properties of CB-03-01 Cream, 1%, applied every twelve hours for two weeks, in pediatric patients 9 to less than 12 years of age with acne vulgaris. Adrenal suppression ef...
What is the current status of trial NCT02720627?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2016-10-28. Estimated completion is 2018-03-21.
What conditions does trial NCT02720627 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT02720627?
The interventions under investigation include: cortexolone 17α-propionate (DRUG).
Who is sponsoring clinical trial NCT02720627?
This trial is sponsored by Cassiopea SpA, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02720627 being conducted?
This trial has 10 study locations across Arkansas, California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
ACTIVE NOT RECRUITING · Phase 2
-
Dose Range Study of CD5789 in Acne Vulgaris
COMPLETED · Phase 2
-
Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris
COMPLETED · Phase 2
-
Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris
COMPLETED · Phase 2
-
A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
COMPLETED · Phase 2
-
Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.